CHRS - Coherus BioScie Charts, Trade Ideas, Earnings, Ratings

TRENDING : Top 50 TRCH (0%) SPY (0%) OCGN (0%) MOXC (0%) MGNI (0%) GSAT (0%) GRWG (0%) GOED (0%) GME (0%) FURY (0%) ETSY (4.21%) ENG (0%) CWH (0%) CRSR (0%) CPE (0%) CELH (0%) BZUN (0%) BFLY (0%) BBIG (0%) BA (0%) AVXL (0%) AU (0%) AMPUSD (%) AMC (0%) ABNB (0%)

CHRS - Coherus BioSciences

$15.07 0[0%]

15 mins delayed data

People also watch : AFMD | ACOR | RGEN

+Watchlist

1 StockHoot Traders following this.
Analyst Ratings | Earnings

Previous Close	$15.07	Open
Volume	72	Market Cap	1.352B
Yield		Last Dividend

Day

52 Week

Polyarticular Juvenile Idiopathic Arthri...	06/10/21
This report studies the Polyarticular Juvenile Idiopathic Arthritis Drug Market with many aspects of the industry like the market size, market status,...

Coherus, Junshi Toripalimab-Chemo Combo ...	06/04/21
Shanghai Junshi Biosciences Co Ltd and Coherus BioSciences Inc (NASDAQ: CHRS ) have announced positive results from the pivotal Phase 3 JUPITER-02 tri...

Coherus and Junshi Biosciences Announce ...	06/02/21
Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announc...

ANALYST RATINGS

1 analyst ratings (Last 3 months)

100.00 %

Strong Buy + Buy

Price Target (PT)

EARNINGS

Date	04/12/2019 (AMC)	Est. (EPS/Rev.)	$1.37
Actual (EPS/Rev.)	$2.5B	EPS (TTM)	$???

TRADERS TRACKING $CHRS

No traders tracking are currently recommending this stock

SHOW ALL TRADERS

About Us

Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.

Product Types

Strategies

Secure Payments

We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.

Total Revenue	$1.3B	Total Liabilities	$2.1B
Cost of Revenue	$2.5B	Total cash flow	$3.2
Total Assets	$29.98B

Vanguard	12.52% (+6.4%)	Bank of America	10.43%
Vanguard	12.52% (+6.4%)	Bank of America	10.43%
Vanguard	12.52% (+6.4%)	Bank of America	10.43%
Vanguard	12.52% (+6.4%)	Bank of America	10.43%
Vanguard	12.52% (+6.4%)	Bank of America	10.43%